Susceptibility of staphylococcus aureus to topical agents in the United States: A Sentinel Study

Clinical Therapeutics

Volumn 36, Issue 6, 2014, Pages 953-960

  Biedenbach, Douglas J ^a   Bouchillon, Samuel K ^a   Johnson, Seth A ^a   Hoban, Daryl J ^a   Hackel, Meredith ^a  

^a International Health Management Associates   (United States)

Author keywords

Bacterial resistance; Mupirocin; Retapa mulin; Skin and skin structure infections; Staphylo coccus aureus

Indexed keywords

CEFALOTIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; METICILLIN; PSEUDOMONIC ACID; RETAPAMULIN; TETRACYCLINE; ANTIINFECTIVE AGENT; FUSED HETEROCYCLIC RINGS;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; GRAM STAINING; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NONHUMAN; OUTPATIENT; PENICILLIN RESISTANCE; QUESTIONNAIRE; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; TOPICAL TREATMENT; UNITED STATES; CLINICAL TRIAL; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; STAPHYLOCOCCAL SKIN INFECTIONS; SURGICAL WOUND INFECTION; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANTI-BACTERIAL AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; CLINDAMYCIN; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MUPIROCIN; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS; SURGICAL WOUND INFECTION; UNITED STATES;

EID: 84902865887     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.04.003     Document Type: Article

References (26)

1. Kirst HA. Developing new antibacterials through natural product research. Expert Opin Drug Discov. 2013;8: 479-493.
2. Novak R. Are pleuromutilin antibiotics finally fit for human use? Ann N Y Acad Sci. 2011;1241:71-81.
3. Novak R, Shlaes DM. The pleuromutilin antibiotics: a new class for human use. Curr Opin Investig Drugs. 2010;11: 182-191.
4. Tang YZ, Liu YH, Chen JX. Pleuromutilin and its derivatives - the lead compounds for novel antibiotics. Mini Rev Med Chem. 2012;12:53-61.
5. Jones RN, Fritsche TR, Sader HS, Ross JE. Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci. Antimicrob Agents Chemother. 2006;50:2583-2586. (Pubitemid 43993211)
6. Jacobs MR. Retapamulin: a semisynthetic pleuromutilin compound for topical treatment of skin infections in adults and children. Future Microbiol. 2007;2:591-600.
7. Scangarella-Oman NE, Shawar RM, Bouchillon S, Hoban D. Microbiological profile of a new topical antibacterial: retapamulin ointment 1%. Expert Rev Anti Infect Ther. 2009;7:269-279.
8. Shawar R, Scangarella-Oman N, Dalessandro M, et al. Topical retapamulin in the management of infected traumatic skin lesions. Ther Clin Risk Manag. 2009;5:41-49.
9. Parish LC, Parish JL. Retapmulin: a new topical antibiotic for the treatment of uncomplicated skin infections. Drugs Today. 2008;44:91-102. (Pubitemid 351596085)
10. Yang LP, Keam SJ. Retapamulin: a review of its use in the management of impetigo and other uncomplicated superficial skin infections. Drugs. 2008;68:855-873. (Pubitemid 351550533)
11. . Moet GJ, Jones RN, Biedenbach DJ, et al. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: Report from the SENTRY Antimicrobial Surveillance Program 1998-2004. Diagn Microbiol Infect Dis. 2007;57:7-13. (Pubitemid 44908825)
12. Weinberg JM, Tyring SK. Retapamulin: an antibacterial with a novel mode of action in an age of emerging resistance to Staphylococcus aureus. J Drugs Dermatol. 2010;9: 1198 -1204.
13. Rittenhouse S, Singley C, Hoover J, et al. Use of the surgical wound infection model to determine the efficacious dosing regimen of retapamulin, a novel topical antibiotic. Anti-microb Agents Chemother. 2006;50:3886-3888. (Pubitemid 44684908)
14. Kosowska-Shick K, Clark C, Credito K, et al. Single- and multistep resistance selection studies on the activity of retapamulin compared to other agents against Staph-ylococcus aureus and Streptococcus pyogenes. Antimicrob Agents Chemother. 2006;50:765-769. (Pubitemid 43190997)
15. Wite W, Cuny C. Emergence and spread of CFR-mediated multiresistance in staphylococci: an interdisciplinary challenge. Future Microbiol. 2011;6:925-931.
16. Woodford N, Afzal-Shah M, Warner M, Livermore DM. In vitro activity of retapamulin against Staphylococcus aureus isolates resistant to fusidic acid and mupirocin. J Anti-microb Chemother. 2008;62:766-768.
17. Li B, Wendlandt S, Yao J, et al. Detection and new genetic environment of the pleuromutilin-lincosamide-streptogramin A resistance gene Isa (E) in methicillin-resistant Staphylococcus aureus of swine origin. J Antimicrob Chemother. 2013;68: 1251 -1255.
18. Clinical Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standards - ninth edition. http://www.google.com/url?sa= t&rct=j&q= &esrc=s&source=web &cd=1&ved=0CCcQFjAA&url=htt p%3A%2F%2Fwww.techstreet.com %2Fproducts%2Fpreview%2F18230 12&ei= NbBGU86VM4Xi0gG1q4C ABA&usg=AFQjCNHwgXsoDltX8 H6jCoBAcKFUHHUBxA&sig2=Ym R1g9QT4aMgUzdfugN3iQ&bvm= bv.64507335,d.dmQ&cad=rjt. Accessed April 10, 2014.
19. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-second informational supplement. http://antimicrobianos.com. ar/ATB/wp-content/uploads/2012/11/M100S22E.pdf. Accessed April 10, 2014.
20. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disk susceptibility tests; approved standards - eleventh edition. http://antimicro bianos.com.ar/ATB/wp-content/uploads/2012/11/01-CLSI-M02-A11- 2012.pdf. Accessed April 10, 2014.
21. Finlay JF, Miller LA, Poupard JP. Interpretive criteria for testing susceptibility of staphylococci to mupirocin. Antimicrob Agents Che-mother. 1997;41:1137-1139. (Pubitemid 27194199)
22. Traczewski MM, Brown SD. Proposed MIC and disk diffusion microbiological cutoffs and spectrum of activity of retapamulin, a novel topical antimicrobial agent. Antimicrob Agents Chemother. 2008; 52:3863-3867.
23. Ross JE, Jones RN. Quality control guidelines for susceptibility testing of retapamulin (SB-275833) by reference and standardized methods. J Clin Microbiol. 2005;43: 6212-6213. (Pubitemid 43100696)
24. Cadilla A, David MZ, Daum RS, Boyle-Vavra S. Association of high-level mupirocin resistance and multidrug-resistant methicillin-re-sistant Staphylococcus aureus at an academic center in the Midwestern United States. J Clin Microbiol. 2011;49:95-100.
25. Jones JC, Rodgers TJ, Brookmeyer P, et al. Mupirocin resistance in patients colonized with methicillin-resistant Staphylococcus aureus in a surgical intensive care unit. Clin Infect Dis. 2007;45:541-547. (Pubitemid 47328632)
26. Patel JB, Gorwitz RJ, Jernigan JA. Mupirocin resistance. Clin Infect Dis. 2009;49:935-941.